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Abstract Identification of the cellular and molecular as-
pects of lung cancer stem cells (LCSCs) that are suggested
to be the main culprit of tumor initiation, maintenance,
drug resistance, and relapse is a prerequisite for targeted
therapy of lung cancer. In the current study, LCSCs sub-
population of A549 cells was enriched, and after charac-
terization of the spheroid cells, complementary DNA
(cDNA) microarray analysis was applied to identify differ-
entially expressed genes (DEGs) between the spheroid and
parental cells. Microarray results were validated using
quantitative real-time reverse transcription-PCR (qRT-
PCR), flow cytometry, and western blotting. Our results
showed that spheroid cells had higher clonogenic potential,
up-regulation of stemness gene Sox2, loss of CD44 expres-
sion, and gain of CD24 expression compared to parental
cells. Among a total of 160 genes that were differentially
expressed between the spheroid cells and the parental cells,
104 genes were up-regulated and 56 genes were down-reg-
ulated. Analysis of cDNA microarray revealed an
embryonic stem cell-like signature and over-expression of
epithelial-mesenchymal transition (EMT)-associated genes
in the spheroid cells. cDNA microarray results were vali-
dated at the gene expression level using qRT-PCR, and
further validation was performed at the protein level by
flow cytometry and western blotting. The embryonic stem
cell-like signature in the spheroid cells supports two im-
portant notions: maintenance of CSCs phenotype by
dedifferentiating mechanisms activated through oncogenic
pathways and the origination of CSCs from embryonic
stem cells (ESCs). PI3/AKT3, as the most common up-
regulated pathway, and other pathways related to aggressive
tumor behavior and EMT process can confer to the spheroid
cells’ high potential for metastasis and distant seeding.
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Introduction
Lung cancer is the most common cancer and the leading cause
of cancer-related death throughout the world [1, 2]. The high
aggressiveness and devastating nature of a variety of tumor
types, including lung cancer, is attributed to the presence of a
subpopulation of extremely high tumorigenic cancer cells
termed cancer stem cells (CSCs) or cancer initiating cells
(CICs) [3]. These hyper-malignant cancer cells have the abil-
ity to initiate and maintain tumor growth, confer resistance to
conventional radio/chemotherapy regimens, and promote re-
currence and metastasis [4, 5]. Detailed knowledge
concerning the genomic profiles of CSCs is required to deter-
mine the genetic changes associated with initiation, progres-
sion, and metastasis of lung cancer. To our knowledge, limited
data is available addressing the gene expression profiling of
lung CSCs [6, 7].
Since CSCs possess common basic characteristics and sig-
nal transduction pathways with normal stem cells, isolation
and characterization of CSCs can be accomplished by using
their phenotypic similarities, including expression of cell sur-
face markers, sphere-forming assays, and dye exclusion [5, 8].
Numerous efforts have been directed to characterize lung
CSCs using putative CSC cell surface markers including
CD133 and CD44, the intracytoplasmic enzyme activity of
aldehyde dehydrogenase 1 (ALDH1) and the efflux of
Hoechst 33342 by the ATP-binding cassette (ABC) family
[7, 9–18]. Despite applying different approaches, no definite
lung CSC marker(s) has been identified for isolation of CSCs
in lung cancer; therefore, further attempts are required to ex-
plore CSCs subpopulation(s) in lung cancer. The ability of
undifferentiated stem cells to form free-floating clusters under
non-adherent conditions, known as spheres, have been widely
used in recent years as an approach for the enrichment of
CSCs in several malignancies including lung cancer [19–22].
Our previous flow cytometric analysis of a panel of puta-
tive stem cell markers in human lung adenocarcinoma epithe-
lial cell line, A549, did not show any specific CSC marker for
this cell line [23]. The self-renewal ability of stem cell allows
for forming as free-floating structures called sphere in suspen-
sion culture in medium not containing serum, and this ap-
proach was widely used for identification of CSCs from var-
ious tissues and malignant tumors [21]. Therefore, in the pres-
ent study, enrichment of CSCs was performed by plating
A549 cells in non-adherent and serum-free conditions. Then,
the spheroid cells were characterized using the colony-
formation assay, quantitative real-time reverse transcription-
PCR (qRT-PCR) for evaluating stemness-related genes and
flow cytometry for determining putative stem cell markers.
In the next phase, gene expression profiling of the spheroid
cells compared to the parental cells was analyzed using com-
plementary DNA (cDNA) microarray to identify differentially
expressed genes (DEGs), distinctive signal transduction
pathways, and gene expression signatures. Since our gene
expression analysis showed significant over-expression of c-
KIT in the spheroid cells, the expression levels of c-KIT pro-
tein was determined by immunohistochemical analysis on tis-
sue microarray (TMA) samples of different subtypes of lung
cancer.
Materials and methods
Cell culture and sphere formation
The human lung adenocarcinoma epithelial cell line A549was
obtained from the Iranian Biological Resource Center (IBRC
C10080, Tehran, Iran) and maintained as monolayer culture in
Dulbecco’s modified Eagle’s medium (DMEM; Gibco,
Invitrogen, USA), 10 % fetal calf serum (FCS; Gibco,
Invitrogen, USA), 2 mML-glutamine, 2 mM non-essential
amino acid, 100 U/ml penicillin, and 100 μg/ml streptomycin
known as a complete medium at 37 °C in a humidified atmo-
sphere containing 5 % CO2.
To form the spheroids, the poly-hydroxyethyl methacrylate
(poly-HEMA) (Sigma, USA) coating was used to prevent cell
adhesion. A stock solution of poly-HEMA was prepared by
dissolving 1.2 g of poly-HEMA in 10ml of 95% ethanol, then
diluted 1:10 to obtain the final solution at 1.2 % and filtered.
Tissue culture flasks were coated with the diluted solution and
allowed to air-dry in a laminar flow hood overnight.
Approximately 7×105 of single viable cells were plated on
poly-HEMA coated tissue culture flasks in serum-free media
as described previously [23]. For passage of spheres with the
mean size of 250–300 μm, the collected free-floating spheres
were washed with PBS, then dissociated by treatment with
trypsin-EDTA and gentle pipetting, re-suspended in serum-
free media to re-form spheres and were passaged every 4–
6 days. In the current study, all comparisons were made be-
tween the third passage sphere-forming cells (termed spheroid
cells) and parental A549 cells (termed parental cells).
Colony-formation assay
For the colony-formation assay, single cell mixture of parental
cells and spheroid cells were prepared, then an equal cell number
of each population was seeded at a density of 80 viable single
cells/well on six-well culture plates in complete medium and
allowed to grow for 10 days. The cell colonies were fixed with
4 % paraformaldehyde and stained with 0.05 % crystal violet
(Sigma, USA). Colonies with more than 50 cells were counted
and colony-forming efficiency was determined by the method
described previously [23]. Moreover, the number of different
colony types (holoclone, meroclone, and paraclone) was deter-
mined in each population. Large colonies with small compact
cells, homogeneous cell morphology, and regular margins were
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identified as holoclone, whereas paraclones were fragmented
assemblies of fully differentiated cells with irregular margins
and aborted cells. The third colony type known as meroclones
harbored heterogeneous cell populations, were medium-sized,
and showed the intermediate structure between holoclones and
paraclones.
Total RNA extraction, cDNA synthesis, and qRT-PCR
Total RNA from parental cells and the spheroid cells were
extracted by the Trizol method (Sigma, USA) according to
the manufacturer’s standard procedures. For complete DNA
digestion, total RNA was treated with RNase-free DNase I
(Fermentas, Germany), and its purity and integrity were deter-
mined by spectrophotometry and agarose gel electrophoresis,
before and after treatment. cDNAwas synthesized from 2 μg
DNase I-treated total RNA using RevertAidTM first Strand
cDNA Synthesis Kit (Fermentas, Germany). Expression of
common stemness genes including c-Myc, Klf4, Sox2, Oct4,
and Nanog was examined by applying qRT-PCR. For each
PCR, 2μl of diluted template cDNA (16 ng/μl) was quantified
using 10 μl of SYBR®Premix Ex Taq™ II (RR081Q, Takara
Bio., Inc.), 6 μl dH2O, and 1 μl each of the forward and
reverse primers (5 pmol/μl) in a Rotor-Gene™ 6000 Real-
Time PCR System (Corbett Life Science, Sydney, Australia)
using the following program: 95 °C for 10 min (stage 1) and
95 °C for 10 s, 60 °C for 20 s, and 72 °C for 20 s (stage 2), for
40 cycles. Average expression of GAPDH gene was used to
normalize expression values. All data are represented as log2-
linear plots. The sequence-specific primers are shown in
Table 1.
Immunophenotyping of promising CSC markers
The protein expression of some putative CSC markers includ-
ing CD24, CD133, ABCG2, and CD44/CD24 were analyzed
in the spheroid cells and compared to parental cells using flow
cytometry. For this purpose, single cell suspensions from each
population were prepared by the method described above, and
then at least 1×105 cells of each population were incubated
with 1 mg/ml of fluorescently labeled monoclonal antibodies
or respective isotype controls at 4–8 °C for 30 min on ice at
dark. After washing, labeled cells were analyzed by flow cy-
tometry using fluorescence-activated cell sorting (FACS) Aria
II (Becton Dickinson, San Jose, CA, USA). The following
antibodies were used for flow cytometry: phycoerythrin
(PE)-labeled mouse anti-human CD133, PE-labeled mouse
anti-human CD44, PE-labeled mouse anti-human ABCG2,
and fluorescein isothiocyanate (FITC)-labeled mouse anti-
human CD24 (all from Dako). All data were analyzed using
CellQuest software (Becton Dickinson, San Jose, CA, USA).
RNA and cDNA preparation for cDNA microarray
Total RNA was extracted from parental cells and spheroid
cells using an RNeasy Mini Kit (Qiagen, USA) according to
the manufacturer’s protocol. Briefly, cell pellets were lysed,
homogenized by RLT buffer (Qiagen), and loaded onto an
RNeasy spin column and centrifuged. Then RW1 buffer
(Qiagen) was added and centrifuged, the remaining contami-
nation was washed by adding modified PRE buffer (Qiagen),
and the RNAwas diluted. In total RNA extraction, RPE buffer
was used for elimination of proteins and salts such as guani-
dine salt. In Qiagen kit (cat number: 74104), buffer RPE is
supplied as a concentrate. Before using for the first time, four
volumes of ethanol (96–100 %) were added to obtain a work-
ing solution.
After evaluation of concentration, purity, and quality of
samples, 50 μg of total RNA from each population were re-
versed transcribed using the Amino Allyl cDNA labeling kit
(Ambion, USA) according to the manufacturer’s instructions.
In the first step, cDNA was constructed from total RNA by
reverse transcription: dTTP was partially substituted with
aminoallyl dUTP, the RNA was removed from the cDNA,
Table 1 Sequence-specific
primers of targeted stemness
genes used for qRT-PCR
Primer Sequence (5′→3′) Product size (bp) Ta (oC)
GAPDH F: CTCATTTCCTGGTATGACAACGA
R: CTTCCTCTTGTGCTCTTGCT
122 60
c-Myc F: ACACATCAGCACAACTACG
R: CGCCTCTTGACATTCTCC
140 60
Klf4 F: ATTACCAAGAGCTCATGCCA
R: CCTTGAGATGGGAACTCTTTG
150 60
Sox2 F: GGGAAATGGAAGGGGTGCAAAAGAGG
R: TTGCGTGAGTGTGGATGGGATTGGTG
151 60
Nanog F: AAAGAATCTTCACCTATGCC
R: GAAGGAAGAGGAGAGACAGT
110 60
Oct4 F: CTGGGTTGATCCTCGGACCT
R: CACAGAACTCATACGGCGGG
128 60
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and the amino allyl-modified cDNAwas recovered by ethanol
precipitation. In the second step, the amino allyl-modified
cDNA was coupled to the fluorescent dye by incubation of
the cDNA with either Cy3 or Cy5 (Amersham Biosciences,
Buckinghamshire, UK), terminated by addition of hydroxyl-
amine, passed through a Nuc-Away Spin Column to remove
the free dye, and the end cDNA concentration and Cy5/Cy3
incorporation were evaluated.
Microarray hybridization, scanning, and data processing
The Ocimum Biosolutions Human Cancer OciChip TM
(Ocimum Biosolutions, India) array was used for comparison
of gene expression profiles of the spheroid cells and parental
cells. This array covers 1853 human genes associated with
cancer progression and spans genes associated with a wide
range of biological pathways including cell cycle control, cell
adhesion, angiogenesis, signaling, and immunity. An equal
amount of each labeled cDNA target was fragmented with a
hybridization buffer (BioTray, Lyon, France) at 94 °C for
5 min using a thermal cycler (Eppendorf, Germany).
Hybridization and washing were performed using the auto-
mated system Tray Mix S4 (BioTray, Lyon, France) based
on the chaotic hybridization approach. After hybridization
and washing, the slides were dried and scanned immediately
with a two-channel cDNA microarray system, ScanArray
Express HT scanner (PerkinElmer, Waltham, MA, USA).
The scanner software recognizes the regions of fluorescent
signal, determines the signal intensity, and compiles the data
into a spreadsheet of fluorescent signals of every probe on the
array. The Lowess normalization method was used to normal-
ize the Cy5:Cy3 intensity ratios for each data point [24]. This
process was carried out for three different biological replicate
of spheroid and parental cells, respectively, to increase the
accuracy. Further analysis of the DEGs selection was per-
formed using GPRocessor 2.0, a software developed at Yale
University (New Haven, CT, USA).
Functional gene analysis, construction of PPI network
and signaling pathway mapping
For functional gene expression analysis, DEGs were submit-
ted to the Visualization and Integrated Discovery (DAVID)
web-based tool (http://david.abcc.ncifcrf.gov/), while for
Gene Ontology (GO) terms, enrichment analysis was applied
(P<0.05). The applied threshold was adopted from fisher ex-
act P value for gene enrichment analysis where P <0.05 rep-
resents significant enrichment. Also, construction of the
protein-protein interaction (PPI) network between DEGs was
performed using the STRING web-based tool (http://string-
db.org) [25]. In reconstructing the pertinent PPI networks,
only interactions with a probabilistic confidence score of at
least 0.4 were selected. Network parameters were analyzed
using a Network Analyzer of Cytoscape (http://www.
cytoscape.org/) for the spheroid cells’ PPI network. A P
value of ≤0.05 was considered to be statistically significant.
To identify the spheroid-specific signaling pathways, all
160 DEGs discovered by the microarray were mapped into
Kyoto Encyclopedia of Genes and Genomes (KEGG),
REACTOME, BIOCARTA, and other signaling pathway da-
tabases [26–28] (the full list of pathway databases can be
found in the Path Guide website, www.pathguide.org).
Based on these signaling pathway databases, and previous
literature, the spheroid-specific signaling pathways were man-
ually constructed using CellDesigner version 4.4 (www.
celldesigner.org) in Systems Biology Markup Language
(SBML) format, which provides the capabilities of graphical
environment, pathway visualization, and navigation.
Validation of cDNA microarray results at the gene level
by qRT-PCR analysis
For validation of cDNA microarray results by qRT-PCR, 15
genes were selected from the DEGs list based on their putative
role in tumor progression and metastasis, epithelial-
mesenchymal transition (EMT), embryonic signaling path-
ways, and putative stem cell markers (Table 2). Sequence-
specific primers were designed with the aid of the primer3
web tool (http://biotools.umassmed.edu/bioapps/primer3_
www.cgi) against the coated nucleotide sequences on the
array slide (Table 3). After determination of the specificity
of each primer set and the molecular weight of the amplicon,
qRT-PCR was performed on a Rotor-Gene™ 6000 Real-Time
PCR System according to the above-mentioned methods.
Specific amplification was confirmed using negative controls
and dissociation curves.
Further validation of cDNA microarray results
at the protein level by flow cytometry and western blot
The protein expression of chemokine (C-X-C motif) li-
gand 12 (CXCL12) also called stromal cell-derived fac-
tor 1 (SDF1), as the most up-regulated transcript in our
spheroid cells, was assessed by western blot. For each
cell population (spheroid and parental cells), 30 μg pro-
teins were separated by 10 % SDS-PAGE gel electro-
phoresis at 100 V for 2 h using a Mini-PROTEAN 3
electrophoresis system (Bio-Rad, Hercules, CA, USA)
and transferred to a PVDF membrane (Amersham) using
a semi-dry blotting method (Bio-Rad) and Dunn carbon-
ate transfer buffer (10 mM NaCHO3, 3 mM Na2CO3,
20 % methanol). After washing, each membrane was
blocked with blocking buffer (5 % nonfat dry milk in
TBS-tween-20 (0.05 %)) for 1.5 h at room temperature
(RT) with gentle agitation. The membranes were incu-
bated with primary antibodies against CXCL12 or
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SDF1) (Cell Signaling, 3740, 1:1000) and GAPDH
(1:20000 as the housekeeping gene or internal control)
for 2 h at RT with gentle agitation. At the end of the
incubation period, the membranes were washed and in-
cubated with the peroxidase-conjugated secondary anti-
body (anti-rabbit (Millipore, Billerica, MA, USA,
1:300000)) for 1 h at RT with gentle agitation.
Eventually, visualization was performed using an ECL
advance western blotting detection kit (GE Healthcare,
USA), and X-ray films (Agfa, Mortsel, Belgium) were
scanned with a densitometer (GS-800, Bio-Rad, USA).
In addition, the analysis of CD24 protein expression in
Table 2 Fifteen genes from
different pathways were selected
for validation by qRT-PCR
Function Gene selected from DEGs
Tumor progression and metastasis CXCL12, CDH6, c-KIT, CD24, PDGFRA
Epithelial-mesenchymal transition (EMT) BMPR1B, FZD4, SMO, c-KIT, WNT10B, CDH6
Embryo lung development and embryonic
signaling pathways
SMO, NOTCH2, WNT10B, BMPR1B, FZD4, c-KIT
Cell cycle G1/S phase transition CDK2
Regulation of programmed cell death BAD
Angiogenesis PDGFRA, SIRT1
Stem cell markers CD24, c-KIT
Components of the extracellular matrix HAS1
Cell proliferation and tumor growth PTH1R, c-KIT
Table 3 Sequence-specific
primers of 15 selected genes for
the validation of microarray data
using qRT-PCR
Primer Sequence (5′→ 3′) Product size (bp) Ta (o C)
CXCL12 F: AAGAACAACAACAGACAAGTG
R: GCAACATGGCTTTCGAAGA
109 60
CDK2 F: TTGTCAAGCTGCTGGATGTC
R: TGGAGCAGCTGGAACAGATA
112 60
PTH1R F: CACCTGTTCCTGTCCTTCAT
R: CTCCACCAGAATCCAGTAGTAG
234 60
BMPR1B F: CAAAGGTCTTGCGTTGTAAATG
R: AGCCTTCTAGTCCTAGGCAACC
150 60
FZD4 F: GGGTCAGTTACCAGTGACCTTC
R: CGTCCCCATCCTAGATCAGTTA
151 60
CD24 F: TCCTACCCACGCAGATTTATTC
R: ACGAAGAGACTGGCTGTTGACT
154 60
c-KIT F: CGAGTTGGCCCTAGACTTAGAA
R: TTGTGATCCGACCATGAGTAAG
140 60
PDGFRA F: TTGGTGAGAGTCCAACAGACAC
R: AGGGAAGTACATGGATGGATTG
152 60
HAS1 F: GATACTGGGTAGCCTTCAATGTG
R: GTTGTACCAGGCCTCAAGAAACT
128 60
SMO F: TATTCCTCTCCCAGGTGTTTGT
R: ACCGCTGAAACTGAACTGAAAT
147 60
BAD F: CGAGTCTTCCAGTCCTGGTG
R: GTACTTCCGCCCATATTCAAGA
137 60
SIRT1 F: TATTTATGCTCGCCTTGCTGTA
R: ACAGAGAGATGGCTGGAATTGT
145 60
NOTCH2 F: ACCTATCTGCATGGACCTCTGT
R: CAATTTGGTCTGACATTGTGCT
151 60
WNT10B F: TGGTCCCTGGAAGCTTAAAGTA
R: GGTGTCTAAGGAGCAGAAGAGG
145 60
CDH6 F: GTCGGTACATTTGTTGTCCAAGT
R: TGTTGAGCAAAGCTGTCTTGATA
151 60
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spheroid cells compared to parental cells was performed
as described in the above section (Immunophenotyping
of promising CSC markers).
Immunohistochemistry of c-KIT
The expression levels of c-KIT protein were examined on a
series of lung TMA, including 51 squamous cell carcinoma
(SCC), 37 adenocarcinoma (ADC), and 8 large cell carcinoma
(LCC) as non-small cell lung cancer (NSCLC), and 26 small
cell lung cancer (SCLC). Immunohistochemistry was per-
formed using rabbit polyclonal anti-c-KIT antibody (Santa
Cruz, USA, dilution 1:50) as described previously [29, 30].
The immunostained TMA slides were evaluated by two ob-
servers (A.K. and Z.M.) and scored based on the intensity of
staining, percentage of positive cells, and histochemical score
(H-score). The latter was assigned by multiplying the staining
intensity by the percentage of positive tumor cells [31].
Statistical analysis
The data concerning the in vitro characterization of spheroid
cells are presented as mean±SD obtained from at least three
different experiments. Student’s t test was performed to eval-
uate the difference between the mean values. The correlation
between c-KIT expression of (as detected by immunohisto-
chemistry) and lung tumor types was evaluated using
Pearson’s χ2 and Pearson’s R tests. Moreover, the expression
level of c-KIT in various subtypes of NSCLC (including SCC,
ADC, and LCC) were compared using Mann-Whitney U test.
Results
Spheroids cells derived from parental cells were
clonogenic and expressed higher levels of Sox2 mRNA
Spheroids from parental cells formed free-floating cellular ag-
gregates and were in a very compact spherical shape (Fig. 1a–
c). The spheroid cells were serially passaged using a similar
procedure and propagated as pulmospheres for nine passages,
but the number and mean size of the spheroids reduced by
serial passage. To explore the cancer stem cell-like properties
of spheroids cells, their colony-forming potential was com-
pared with parental cells. The spheroid cells, similar to paren-
tal cells, were able to form three kinds of colonies with differ-
ent characteristics including holoclone, meroclone, and
paraclone (Fig. 1d). The spheroid cells formed significantly
more holoclones (P=0.003) and paraclones (P<0.001) than
the parental cells (Fig. 1e). The parental cells displayed
colony-forming potential of 56.66±0.72 % with mean colony
size of 2919±146 μm, whereas colony-forming potential for
spheroid cells was 67.08±0.72 % with mean colony size of
5549±277 μm. Therefore, the spheroid cells showed signifi-
cantly higher clonogenic capacity (P<0.001) (Fig. 1e) and
larger colonies (P=0.009) (Fig. 1f) than parental cells. For
further characterization of spheroids, expression of
stemness-related genes c-Myc, Nanog, Klf4, Oct4, and Sox2
in the spheroid cells were compared with the parental cells.
The spheroid cells expressed higher levels of Sox2 (P=0.038)
and Oct4 (P>0.05) and lower levels of c-Myc (P=0.04) and
Nanog (P>0.05) genes. There was no significant difference in
the expression of Klf4 gene between the two populations
(Fig. 1g).
Loss of CD44 expression and gain of CD24 expression
in spheroid cells
Flow cytometric analysis of putative stem cell markers
CD44/CD24 demonstrated that parental cells expressed
CD44+/CD24+ at mean level of 64.1±2.02 %, whereas the
mean level of CD44+/CD24+ expression in the spheroid cells
was 51.02±0.9 % (Table 4). Furthermore, the mean expres-
sion of CD44+/CD24−/low population was 27.92±3.63 % and
15.47±1 % in parental cells and spheroid cells, respectively
(Table 4). These findings revealed that the CD44+/CD24+ and
CD44+/CD24−/low populations were significantly smaller in
the spheroid cells compared to the parental cells (P=0.002
and P=0.02, respectively). Our results showed that CD44−/
CD24+ cells were not frequently found in parental cells (mean
±SD; 0.2±0.3 %), whereas CD44−/CD24+ was expressed in
13.73±0.7 % of spheroid cells (Table 4). Moreover, CD44−/
CD24−/low cells constituted less than 2 % of parental cells
(mean±SD; 1.68± 0.69 %), but 19.78± 0.4 % of spheroid
cells expressed CD44−/CD24−/low (Table 4). These findings
suggest that the CD44−/CD24+ and CD44−/CD24−/low popu-
lations were significantly higher in the spheroid cells com-
pared to parental cells (P=0.0002 and P<0.0001, respective-
ly). Also, the evaluation of promising stem cell markers
CD133 and ABCG2 by flow cytometry showed no significant
difference between the spheroid and parental cells (P>0.05).
Spheroid cells derived from parental cells displayed
embryonic stem cell-like gene expression signature
Comparison of the gene expression pattern of spheroid cells
with parental cells (with cutoff signal log ratio ≥1 or ≤−1 [24])
Fig. 1 Characterization of the spheroids derived from A549 lung
adenocarcinoma cells. a–c The spheroid cells were free-floating clusters
of compacted cells. d Three colony types named as holoclone, meroclone
and paraclone were identified during the colony-formation assay in both
parental and spheroid cells. e The potential of clonogenicity and f the size
of colonies were significantly higher in the spheroid cells. g Evaluation of
stemness-related genes using qRT-PCR. Spheroid cells had significantly
higher expression level of Sox2 and lower expression level of c-Myc.
Data is presented as mean± SD of at least three different experiments
>
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revealed that 160 transcripts were differentially expressed:
104 genes were up-regulated and 56 were down-regulated.
A complete list of DEGs is provided as supplementary file
1. Official symbols were used according to the genes’ IDs
and lists were approved by the Human Gene Nomenclature
Commit tee (HGNC) (ht tp: / /www.gene.ucl .ac .uk/
nomenclature/)[32].
The DEGs were functionally categorized using the
Visualization and Integrated Discovery (DAVID) web-based
tool (http://david.abcc.ncifcrf.gov/); while for Gene Ontology
(GO) terms, enrichment analysis was applied (P<0.05) [33].
Thus, DEGs were categorized into 11 groups according to
their function, including positive regulation of cell prolifera-
tion, positive regulation of macromolecule metabolic process,
regulation of apoptosis, regulation of programmed cell death,
cell surface receptor linked signal transduction, protein mod-
ification processes, cellular protein metabolic processes, reg-
ulation of nucleic acid metabolic processes, regulation of gene
expression, and regulation of cellular biosynthetic processes
(Fig. 2).
Eleven signaling pathways including phosphatidylinositol
3-kinase/AKT (PI3K/AKT), Ras, Rap1, RAS-mitogen acti-
vated protein kinase/extracellular signal-regulated kinase
(MAPK/ERK), Janus kinases/signal transducers and activa-
tors of transcription (JAK/STAT), AMPK, nuclear factor
kappa-B (NF-kB), TNF, P53, Hedgehog, and Notch pathways
were found to be preferentially expressed in the spheroid cells
compared to the parental cells (Table 4). Thirty-two genes (26
were up-regulated and six down-regulated) were mapped by
bioinformatics’ tools and assigned to these pathways. Some of
the genes could be mapped in multiple pathways, including
inhibitor of nuclear factor kappa-B kinase subunit gamma
(IKBKG) (five signaling pathways), alpha-type platelet-de-
rived growth factor receptor (PDGFRA) (four signaling path-
ways), and insulin-like growth factor 1 (IGF-1) receptor
(IGF1R) and v-kit Hardy-Zuckerman 4 feline sarcoma viral
oncogene homologue (c-KITor CD117) (three signaling path-
ways) (Fig. 3 and Table 5). The most up-regulated gene in the
spheroid cells was chemokine (C-X-C motif) ligand 12
(CXCL12) which plays a critical role in tumor progression
and metastasis [34]. Furthermore, a number of genes known
to be involved in epithelial-mesenchymal transition (EMT)
process, a prerequisite for cancer invasion and metastasis,
were detected in the list of DEGs, including cadherin-6
(CDH6), matrix metallopeptidase14 (MMP14), and
wingless-type MMTV integration site family, member 10B
(WNT10B). Spheroid cells also overexpressed RAB27A (a
member of RAS oncogene family), RAB36 (a member of
RAS oncogene family), and RAB10 (a member of RAS on-
cogene family) that promote metastatic behavior in cancer
cells. In parallel with the flow cytometry results for character-
ization of spheroid cells, over-expression of the putative em-
bryonic stem cell marker CD24 was also noted in the DEG
analysis.
Construction of the spheroid cells PPI network
In the PPI network of the spheroid cells with 105 nodes and
154 edges, cyclin-dependent kinase 2 (CDK2) was a hub gene
with the highest connectivity degree of 14 and after that
MRE11A gene is located with connectivity degree of 11
Table 4 Flow cytometric analysis of putative stem cell markers
CD44/CD24, CD133, and ABCG2 in the spheroid cells compared to
parental cells
Putative marker Mean percentage of positive cells ± SD
Spheroid cells (%) Parental cells (%)
CD44+/CD24+ 51.2 ± 0.9 64.1 ± 2.02
CD44+/CD24−/low 15.47 ± 1 27.92 ± 3.63
CD44−/CD24+ 13.73± 0.7 0.2 ± 0.3
CD44−/CD24−/low 19.78± 0.4 1.68 ± 0.69
CD133 0.36 ± 0.07 0.94± 0.05
ABCG2 0.15 ± 0.02 0.91± 0.05
Fig. 2 Differentially expressed
genes (DEGs) were categorized
into 11 groups according to their
function
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(Fig. 4). The order of high to low connectivity degree was
BLM, TOP1, SIRT1, WRN, ERCC5, SMARCA4, PSEN1,
and BCL6. CDK2, SMARCA4, and BCL6 were components
of sub-network-1 and other genes, except for SIRT1, and
PSEN1 were interacting in the sub-network 2 (Fig. 4).
cDNA microarray results showed a robust correlation
with qRT-PCR analysis
The reproducibility of the microarray data was confirmed by
qRT-PCR analysis of a panel of selected genes. Comparison of
the spheroid cells with the parental cells demonstrated that
changes in gene expression levels were similar to the array
data, in 13 out of the 15 studied genes, and there was a robust
correlation between microarray data and qRT-PCR gene ex-
pression results (86.66 %) (Fig. 5a). All data are presented as
log2-linear plots.
Protein levels of CD24 and CXCL12 were increased
in spheroid cells
The mean expression level of putative stem cell marker CD24
was 55.3±1 % in parental cells, whereas the spheroid cells
expressed CD24 at 68.1±0.7 % mean level. Therefore, CD24
expression was significantly increased in the spheroid cells
compared to the parental cells (P=0.002). Furthermore, the
increased level of CXCL12 protein expression (a protein in-
volved in tumor progression and metastasis), was confirmed
by western blotting. Thus, both CXCL12 protein and tran-
script were highly overexpressed in the spheroid cells com-
pared with parental cells (Fig. 5b).
Elevated expression of c-KIT in ADC tumors
Since up-regulation of c-KIT gene was observed at DGEs list;
we performed immunohistochemical analysis to explore
expression c-KIT protein in various lung tumor subtypes.
Normal lung tissue was included in each block of tissue array
as a normal control for expression of c-KIT. Expression of c-
KIT protein was not detected in normal lung tissues. Since
A549 cell is a human lung adenocarcinoma epithelial cell line,
in the current study, we compared the expression levels of c-
KIT in ADC with SCC, LCC, and SCLC.
The expression of c-KIT was elevated in 78 % (29/37)
ADC and 71 % (36/51) SCC, whereas only 37 % (3/8) LCC
showed increased expression of c-KIT (Fig. 6). A significant
correlation was evident between the level of c-KIT expression
and tumor type (P=0.046), indicating that NSCLC tumor
samples expressed higher levels of c-KIT compared to
SCLC samples. In addition, Mann-Whitney U test analysis
revealed that ADC tumor samples expressed higher levels of
c-KIT compared to LCC (P= 0.02) and SCLC (P= 0.02)
samples.
Discussion
Cancer stem cell theory implies that a distinct subset of cells
with stem cell properties including self-renewal capacity, high
resistance to chemotherapy, and radiation and metastasis po-
tential are the main culprit in initiation and propagation of
neoplasia, including lung cancer [2, 3, 35]. Although surface
marker-based approach is the most widely used method for
identification of CSCs, currently there is no universal consen-
sus concerning the best CSC marker(s) for lung cancer [3, 8,
36]. In addition, the specificity and reliability of these markers
for isolation of CSCs is not well established [8, 36].
Accordingly, sphere assays have been used for enrichment
of CSCs in many tumor types [21, 36]. Thus, we enriched
cancer stem-like cells in A549 cell line under non-adherent
and SFM conditions, as described in our previous report [23].
Then the spheroid cells were characterized using colony-
Fig. 3 The differentially expressed pathways between the spheroid cells
and parental cells. Component of each pathway is shown with a distinct
color, whereas up-regulation and down-regulation of each pathway is
depicted with red and green colors, respectively (from left to the right;
PI3/AKT: blue, NF-kB: dark green, MAPK/ERK: purple, JAK/STAT:
pale pink, Hedgehog: pale green, Notch: orange, Ras: yellow, Raf1:
dark blue, AMPK: gray, TNF: dark pink, P53: pale orange)
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forming assay and analysis of stemness markers at the gene
and protein levels. Colony-formation assay of these cells re-
vealed higher clonogenic capacity, larger size of colonies, and
higher holoclone-forming ability, all considered to be cancer
stem cell-like features [19, 37, 38]. Over-expression of Sox2
was also found in the spheroid cells compared to the parental
cells, which is strongly related to the maintenance of stem cell
properties and tumorigenesis potential of lung CSCs, as well
as the enhancement of cellular invasion and anchorage-
independent growth of these cells [39–42]. Notably, flow cy-
tometric analysis of the spheroid cells indicated loss of CD44
expression and gain of CD24 expression (CD44−/CD24+) in
spheroid cells which is in parallel with our previous report
showing that CD44+/CD24+ and CD44+/CD24−/low subpopu-
lations do not represent CSC subpopulation of A549 cells
[23]. The CD44/CD24 phenotype has not been previously
investigated in lung cancer clinical samples, but a report by
Jaggupilli et al. indicated no expression of both potential
markers CD44 and CD24 in NSCLC cell line COR L23
[43]. Evaluation of CD44/CD24 phenotype in other cancer
types has suggested a subpopulation of CD44+/CD24−/low
cells as breast CSCs population, and CD44+/CD24+ pheno-
type as potential CSC marker in ovarian, pancreatic, and co-
lorectal cancer [44–47]. Therefore, expression of CD44 and
CD24 is highly variable in various cancer cell lines and tis-
sues, including lung cancer. The CD44+/CD24−/low correlates
with better survival and CD44−/CD24+ and CD44−/CD24−/low
phenotypes correlate with poor prognosis and shorter survival
in breast cancer patients [48–50]. Collectively, these data
demonstrated that the spheroid cells derived from A549 cells
can be considered as a cancer stem-like cell population [35,
37, 38, 51].
Monitoring of gene expression profiling demonstrated that
160 genes were differentially expressed between the spheroid
cells as cancer stem-like cells and parental cells as low tumor-
igenic cells. The list of DEGs was categorized into three main
groups; the first group contains genes involved in PI3K/AKT,
MAPK/ERK, JAK/STAT, NF-κB, Wnt, TGF-β, Hedgehog,
and Notch signaling pathways. All of these networks have
been previously identified as embryonic stem cell (ESC)-as-
sociated signaling pathways [52, 53], which implies that CSCs
Table 5 Important signaling pathways which are turned-on in the
spheroid cells
Signaling pathways specific for embryonic stem cells
Pathway Gene name Fold change (spheroid cells/
parental cells)
PI3K/AKT CDK2 4.43
IGF1R 3.15
LPAR2 3.07
PDPK1 2.85
c-KIT 2.74
PDGFRA 2.59
BAD 2.28
PRLR 2.27
IKBKG −2.02
BCL2L1 −3.1
MAPK/ERK RELB 4.06
CDC25B 3.84
MAP2K3 3.51
DUSP3 2.68
PDGFRA 2.59
IKBKG −2.02
JAK/STAT TPO 3.18
PRLR 2.27
IL11 2.19
SOCS2 2.15
BCL2L1 −3.1
NF-kB CXCL12 12.39
RELB 4.06
IKBKG −2.02
BCL2L1 −3.1
Hedgehog SMO 2.46
Notch PSEN 2.18
Signaling pathways related to epithelial-mesenchymal transition (EMT)
Pathway Gene name Fold change
Ras IGF1R 3.15
c-KIT 2.74
PDGFRA 2.59
BAD 2.28
IKBKG −2.02
RAB5C −2.23
BCL2L1 −3.1
Rap1 MAP2K3 3.51
IGF1R 3.15
LPAR2 3.07
c-KIT 2.74
CTNND1 2.72
PDGFRA 2.59
AMPK IGF1R 3.15
PDPK1 2.85
RAB10 2.05
SIRT1 −2.07
TNF MAP2K3 3.51
Table 5 (continued)
RIPK3 2.58
MMP14 2.16
IKBKG −2.02
Signaling pathways related to DNA repair
Pathway Gene name Fold change
P53 CDK2 4.43
DDB2 3.42
PMAIP1 −2.22
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can originate from ESCs. Although some observations sup-
port the notion that the accumulation of DNA damage hits and
later genetic reprogramming may convert normal stem cells to
CSCs, currently there is no consensus regarding the origin of
CSCs [54–58].
Our findings demonstrated that PI3K/AKT is the most im-
portant signaling pathway in the spheroid cells as cancer stem-
like cells and its effects are mediated through the activation of
NF-κB pathways (Fig. 3), which is consistent with previous
reports in acute malignant leukemia and breast and prostate
Fig. 4 Protein-protein interactions (PPI) network and the important sub-
networks of differentially expressed genes (DEGs) in the spheroid cells
reconstructed using STRING database. PPI networks are presented in an
undirected graph format, with nodes (red nodes = up-regulated genes and
green nodes = down-regulated genes) corresponding to proteins; and
edges corresponding to physical protein-protein interactions
Fig. 5 Validation of microarray data using a qRT-PCR analysis:
validation of average gene expression changes in the spheroid cells as
compared to the parental cells when detected by microarray technique
(black bar) and qRT-PCR analysis (gray bar). bWestern blots analysis of
CXCL12 protein expression. Equal amounts of protein from total cell
lysates of parental cells and the spheroid cells were loaded and
analyzed using antibodies against CXCL12. GAPDH was used as an
internal control
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CSCs [59–61]. Subsequently, we showed that activation of the
NF-κB pathway causes over-expression of CXCL12 which
was the most highly up-regulated gene in the spheroid cells
in our current study (12.3-fold) (Fig. 3). CXCL12 binds to
CXC receptor 4 (CXCR4) and leads to activation of the
PI3K/AKT-NF-κB axis and thus facilitates angiogenesis, tu-
mor progression and metastasis [34].
Prior research implies that expression of CXCR4 regulates
CXCL12 expression which in turn enhances aggressive tumor
behavior and metastasis in NSCLC, and knockdown of this
axis can be considered as a potential therapeutic target [62,
63]. Additionally, activation of PI3K/AKT pathway in our
spheroid cells was parallel with increased expression of
CDK2 and BAD molecules and decreased expression of
Bcl-xL (Fig. 3) which leads to apoptosis [64]. Similar to stud-
ies in breast and ovarian CSCs [65–67], activation of
MAPK/ERK and JAK/STAT pathways was detected in our
spheroid cells (Fig. 3) which supports the notion that these
pathways promote cancer stem-like cell properties. Up-
regulation of PI3K/AKT, MAPK/ERK, and NF-κB pathways
are responsible for ESCs’ pluripotency [68].
In the second gene group, we found DEGs which are part
of Ras, Rap1, AMPK, and TNF pathways and EMT process
which are implicated in cancer migration, invasion, and
metastasis [69–75]. In this group, Ras pathway is the most
important cellular pathway, which promotes cytoskeletal re-
modeling through RAB5C (Fig. 3). Activation of both the
RAS and PI3K/AKT pathways was found in our spheroid
cells which are reported to accelerate tumor progression and
metastasis in prostate CSCs [71]. Activation of Rap1 pathway
in spheroid cells was observedwhich lead to increased expres-
sion of CTNND1 and MAP2K3 (Fig. 3). Activation of Rap1
pathway and over-expression of CXCL12 in our study is sim-
ilar to previous reports implying that activation of Rap1 path-
way promotes cell proliferation and metastatic progression in
several tumor types including melanoma, pancreas, and pros-
tate cancer, which in turn lead to the over-expression of
CXCL12 [69, 73–75]. We also found the over-expression of
MMP14 in the context of TNF pathway (Fig. 3), a pattern that
has been shown to lead to the disruption of the extracellular
matrix and provide a unique environment for cell migration
and metastasis [72]. Furthermore, we found the over-
expression of several DEGs with key roles in the EMT pro-
cess, including c-KIT (threefold), IGF1R (threefold),
PDGFRA (2.6-fold), Annexin 2 (2.5-fold), MMP14 (two-
fold), and low expression of CDH6 (tenfold). EMT is con-
trolled by a complex network of events during tumorigenesis
that orchestrate cells for migration to distant sites, thus
Fig. 6 Representative photographs of the immunohistochemical staining of c-KIT from lung cancer patients. a 0 = no staining. b +1 =weak. c
+2 =moderate. d +3= strong intensity of staining (×200 magnification)
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forming metastatic foci [76, 77]. Our findings demonstrated
increased activity of PI3/AKT, MAPK/AEK, Hedgehog,
Notch, Ras, and NF-κB signaling pathways in spheroid cells
that confirm previous studies suggesting these pathways may
contribute to the EMT process [78–80]. In addition, a notice-
able decrease in CDH6 expression, a membrane-bound gly-
coprotein involved in the adherence of adjacent cells, was
detected in spheroid cells in our study; which is known to be
a critical step in promoting EMT [81, 82]. Also, it is shown
that the loss of E-cadherins, including CDH6 in primary tu-
mors is related to tumor metastasis and poor prognosis in lung
cancer patients [83, 84].
RAB GTPases family facilitates exosome formation and
mediates intercellular communications [85, 86]. Of note, high
expression of several elements of RAB GTPases family in-
cluding RAB27a (3.5-fold), RAB36 (2.4-fold), and RAB10
(twofold) was seen in spheroid cells. Some previous studies
have shown that exosomes-derived CSCs could be involved
in angiogenesis, pre-metastatic niche formation, tumor pro-
gression, and metastasis [85, 86].
Additionally, our study showed the elevated expression of
carcinoembryonic antigen-related cell adhesion molecule 1
(CEACAM1) (3.86-fold) in the spheroid cells; over-
expression of CEACAM1 in breast CSCs correlate with an-
giogenesis and metastasis potential, as well as promotion of
invasion and recurrence of colon cancer and hepatocellular
carcinoma [87–89]. Expression of CD24, associated with tu-
mor progression and metastasis [43, 90], was also up-
regulated (3.2-fold) in spheroid cells. In addition to the diag-
nostic and prognostic values, CD24 when co-expressed along
with other putative markers such as CD44 and CD29 has been
used for isolating CSCs from various tumors [54, 91, 92].
We also explored the probable interactions among DEGs
with reconstructing the PPI network for the studied genes,
considering that finding reliable sub-network markers can
help in assessing the tumorigenecity, biomarker discovery,
and also more accurate classification of cancer [93, 94].
CDK2, as a stopping point for G1/S phase transition, was
located at the core of the network; over-expression of CDK2
is shown to be involved in the maintenance of pluripotency of
stem cells [95]. MRE11A, a component of MRN complex as
major sensor of DNA double-strand breaks, was the second
most important molecule in the spheroid cells’ PPI network
[96]. MRN complex is related to carcinogenesis, aggressive
tumor behavior, induction of EMT, and poor prognosis
[97–101]. Additionally, we found simultaneous over-
expression of MRE11A and activation of PI3/AKT pathway
in the spheroid cells; this pattern is previously reported to
correlate with higher content of CSCs in various tumors [96].
The well-known characteristics of CSCs are long-
term self-renewal capacity, multilineage differentiation,
resistance to apoptosis, and drug resistance. This pheno-
type is tightly orchestrated by multiple regulatory
networks and mediated by interaction or crosstalk be-
tween them, as well as the cancer cell microenviron-
ment [102, 103]. Our results are highly suggestive of
crosstalk between the dedifferentiation pathways which con-
fer maintenance of self-renewal and pluripotency features to
tumors, including the CSC subpopulation of tumors and that
of the pathways associated with tumor aggressiveness, distant
metastatic seeding, and EMT which are features commonly
attributed to the CSC subpopulation of tumors.
Our gene expression data was validated at the gene
level using qRT-PCR analysis which showed a robust
correlation with cDNA microarray data. The expression
levels of BMPR1B and FZD4 in cDNA microarray
analysis were changing in opposite directions as com-
pared to the results of qRT-PCR analysis; however, this
discrepancy was not statistically significant.
Our immunohistochemical analysis showed no ex-
pression of c-KIT in lung tissues and highest expression
of c-KIT was found in ADC of lung compared with
other subtypes of lung tumors. These data implies that
c-KIT may be considered as potential molecule for
targeted therapy in lung cancer, especially for ADC.
There is no consensus among the previously published
reports concerning the c-KIT expression in lung cancer
[104–107]. Levina et al. showed the significant role of
c-Kit in self-renewal of lung CSCs and its potential role
in targeted therapy [104]. Moreover, some studies have
shown that c-KIT can be a negative prognostic factor in
NSCLC; other studies demonstrated that there is no as-
sociation between c-KIT and SCLC tumor progression
[105–107].
Conclusions
Embryonic stem cell-like gene expression signature of the
spheroid cells strongly support the notion that maintenance
of CSCs phenotype is achieved by dedifferentiating mecha-
nisms activated through tumor-specific signaling pathways,
and also support the hypothesis that CSCs are originated from
ESCs. Additionally, increased activity of PI3/AKT, as the
most prominently up-regulated pathway, and other pathways
related to tumor progression, aggressiveness, and EMT in the
spheroid cells imply that CSCs are indeed involved in tumor
metastasis and seeding to distant organs. Of note, PPI network
analysis revealed robust activation of some key proteins relat-
ed to DNA damage repair in the spheroid cells, including
MRE11A. The above-mentioned findings can pave the way
for drug discovery and targeted therapy of lung cancer by
identifying the specific molecular pathways in CSCs, inacti-
vation of which can lead to the highest degree of tumor re-
gression and therapeutic gain.
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